LC-MS/MS as a First-Line Screening Assay

Evaluating Alzheimer’s Disease, Growth-Hormone, and Hemoglobin-Related Disorders

Wednesday, July 27
7 – 8:30 a.m.
Hyatt Regency, Regency Ballroom E
Sponsored by Thermo Fisher Scientific


There is an ever-increasing catalog of endogenous biological proteins and peptides, lipids, and metabolites that are being used in clinical settings to better understand disease detection as well as to guide therapeutic treatments. Implementation of mass spectrometry as an aid in clinical diagnosis has grown significantly in the last decade due to its advantages in multi-analyte detection, high analytical specificity, and sensitivity. This workshop covers areas of testing where LC-MS/MS has proven to be a more accurate, reliable, and—at times—a less invasive and faster approach than traditional techniques.


After attending this session, participants will be able to:

  • Demonstrate the utility of high-resolution mass spectrometry (HRAM-MS) in the clinical laboratory.
  • Understand traditional hemoglobinopathy/thalassemia diagnosis methods.
  • Understand the emerging role of blood-based biomarkers in the diagnosis and clinical care of patients with Alzheimer’s disease.


Bradley Hart
Strategic Director, Analytical Sciences and LSMS Marketing Clinical Research and Toxicology
Thermo Fisher Scientific

Sridevi Devaraj, PhD, DABCC, FAACC, FRSC, CCRP
Texas Children’s Hospital

Joel Braunstein, MD, MBA
Chief Executive Officer
C2N Diagnostics

Zengru Wu, PhD
Quest Diagnostics